Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3–14 years: A prospective cohort study

Salleras, L.; Domı́nguez, Àngela; Pumarola, Tomás; Prat, A.; Marcos, Ma Ángeles; Garrido, P.; Artigas, Ricard Mellado; Bau, Abd. Syukur; Brotons, J.; Bruna, Xavier; Catala, Pascale; Carreras, Eduardo; Cuadra, Dante Edin; Gatell, Anna; Millet, Sandrine; Oller, Jr. John W.; Raga, E.

doi:10.1016/j.vaccine.2006.05.034

Cited by 41 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The possible economic impact of a single dose administration in unprimed children was tested by sensitivity analysis, since studies assessing the clinical equivalence of the two modalities (one or two doses in unprimed children) are still ongoing. 27 Immunisation was supposed to be conducted during office hours by Local Health Units, which are usually in charge of the administration of other paediatric vaccines. The unit cost of inactivated influenza vaccine for the Local Health Units may vary according to the product and to local contracts.…”

Section: Methodsmentioning

confidence: 99%

Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age

Marchetti

Kühnel

Colombo³

et al. 2007

Human Vaccines

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age

Marchetti

Kühnel

Colombo³

et al. 2007

Human Vaccines

View full text Add to dashboard Cite

“…Recently, a virosomal-adjuvanted subunit influenza vaccine was shown to be well tolerated and endowed with improved immunogenicity. [36][37][38][39][40] To evaluate the amplitude and duration of the cellmediated and humoral immune responses elicited by such vaccine preparation in pediatric HIV infection, we designed a study protocol enrolling HIV-infected children in whom long-term HAART resulted in an optimal immunovirologic response to therapy.…”

mentioning

confidence: 99%

Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy

Viganò¹,

Zuccotti²,

Pacei³

et al. 2008

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

“…91 Liposomes that also comprise lipid or other material derived from virus are known as virosomes, with material from influenza virus such as hemagglutinin (HA) and neuraminidase being commonly used. [92][93][94][95][96][97][98][99][100][101][102] Currently there is more evidence to support the hypothesis that particles smaller than 300nm are the most effective at crossing mucus, 103 but there is also evidence to suggest that larger particles are also able to penetrate. Results from intranasal administration of mucoadhesive microparticles suggest that penetration of the entire particle may not be necessary to induce an immune response.…”

Section: Formulation Approachesmentioning

confidence: 99%

Current prospects and future challenges for nasal vaccine delivery

Yusuf

Kett

2016

Human Vaccines & Immunotherapeutics

124

View full text Add to dashboard Cite

Nasal delivery offers many benefits over traditional approaches to vaccine administration. These include ease of administration without needles that reduces issues associated with needlestick injuries and disposal. Additionally, this route offers easy access to a key part of the immune system that can stimulate other mucosal sites throughout the body. Increased acceptance of nasal vaccine products in both adults and children has led to a burgeoning pipeline of nasal delivery technology. Key challenges and opportunities for the future will include translating in vivo data to clinical outcomes. Particular focus should be brought to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that stand to benefit from this unique mucosal route. In this review the current state of the art in nasal vaccine delivery will be described along with future prospects. A brief introduction to the anatomy and physiology of the nasal cavity will highlight the advantages and disadvantages of the route. Encapsulation and presentation methods along with particular formulation considerations for the nasal route will also be discussed.There are many mucosal routes which have been regarded as potential sites for vaccine delivery such as oral, nasal, pulmonary, conjunctival, rectal and vaginal mucosa. However, for practical and cultural reasons researchers have tended to focus only on oral, nasal, and pulmonary administration. 1 Needlefree vaccines offer many advantages over traditional vaccination approaches including convenience, cost, ease of administration and disposal.There are several needle free methods of vaccination such as transdermal delivery and mucosal delivery. 2,3 Mucosal immunization has been successfully used in human vaccination. The human mucosal immune system is large and specialized in performing inspection for foreign antigens to protect the surfaces themselves and of course human body interior. Since most infections affect or start from mucosal surfaces, using a mucosal route of vaccination is of great interest and provides a rational reason to induce a protective immune response. 3 Nasal delivery of vaccine offers an easily accessible route to the immune system.The nose has the function of olfactory detection (sense of smell) and also filtration, humidification and temperature control of air as it enters the respiratory system. Moving from front to back the areas of the nasal cavity are the nasal vestibule, the respiratory region, and the olfactory region. The nasal cavity is divided by the septum to form the left and right nares, which lead into the left and right choana before opening onto the nasopharynx at the top of the throat. The turbinates bound the nasal walls and are responsible for air conditioning and the large mucosal surface area of the nasal cavity. The nose is also the main port of entry for many pathogens. The first barrier to foreign bodies is hair at the entrance to the nares, the nostrils, which successfully keeps ou...

show abstract

Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3–14 years: A prospective cohort study

Cited by 41 publications

References 21 publications

Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age

Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age

Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy

Current prospects and future challenges for nasal vaccine delivery

Contact Info

Product

Resources

About